MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock...
$9,000,000
Net cash (used in)
provided by financing...
$4,825,291
Canceled cashflow
$4,174,709
Net increase
(decrease) in cash
$1,421,654
Investment in license
agreement
$132,117
Canceled cashflow
$3,403,637
Payments on notes payable
$3,372,112
Equity issuance costs
$802,597
Change in fair value of
derivative...
$4,089,753
Prepaid expenses and
other assets
-$491,617
Asset impairment loss
$402,746
Stock-based compensation
$20,783
Accounts payable and
accrued expenses
$1,431
Net increase
(decrease) in cash
$1,421,654
Canceled cashflow
$132,117
Net cash used in
operating activities
-$3,271,520
Net cash used in
investing activities
-$132,117
Canceled cashflow
$5,006,330
Net cash used in
investing activities
-$132,117
Net loss
-$8,277,850
Investment in license
agreement
$132,117
Back
Back
Cash Flow
source: myfinsight.com
Hepion Pharmaceuticals, Inc. (CTRVP)
Hepion Pharmaceuticals, Inc. (CTRVP)